Friday, 16th March Eradicate Cancer 2018

Stephanie Ting
Label-Free Real-Time Monitoring of Immune Cell-Mediated Killing Using Cellular Impedance

• CD19 CAR-T cell immunotherapy for B cell malignancies - Cameron Turtle
• Using Chimeric Antigen Receptor (CAR) T cell to Treat Solid Tumours - Clare Y Slaney
• Generating dual-specific T cells in treating cancers - Aesha Ali
• The development, functional evaluation and optimisation of CAR-T cells attacking novel epitopes on ovarian cancer - Vera Evtimov
• Chimeric antigen receptor T cells and the immune synapse - Misty Jenkins
• Validation of a novel CAR-T cell targeting non functional P₂X7 - Simon C Barry
• Optimisation of third-generation CAR T cells for the treatment of solid tumours - Tessa Gargett

• Immunotherapy with antigen specific T cells - Helen Heslop
• Mass cytometry and a systems biology – new tools to explore the biological effects of adoptive T cell therapy - Emily Blyth
• Using cell banks to treat opportunistic infection and haematological malignancy - David Gottlieb
• Orthogonal approaches to regulate CAR T cell activity and safety - Daniel Powell

12:45 - 13:00
LONZA - Dr. Andrea Toell, Senior Product Manager. Lonza Cologne GmbH
Efficient and Scalable Non-viral Modification of Primary Cells and Cell Lines

Lunch and Learn Session:

Thursday 15th and Friday 16th March

Time: 12.30-12.40pm

Where: Booth #2

ATCC "Lunch and Learn session"

Topic: How should you pick and choose cell lines for your cancer research.

More info? https://lifescience.invitro.com.au/l/eradicate-cancer/

• Cbl-b – towards a new paradigm in T cell based anti-cancer therapy - Josef Penninger
• Allogeneic Graft vs Tumor effect: pros, cons and pointers for the future - David Ritchie
• SOCS protein regulation of NK cell-mediated tumour immunity - Sandra Nicholson
• Emerging Advances in Cellular Therapies for Virus-Associated Cancers - Rajiv Khanna
• Predicting and enhancing benefit of immunotherapies in triple negative breast cancer - Belinda Parker
• The importance of Immune-modulation in the management of cancer - Angus Dalgleish

• Predicting the future of novel immunotherapy agents for Haematological Malignancies: one size does not fit all - Miles Prince
• Developing novel therapies to treat cancer based on targeting the nucleolus - Ross Hannan
• Interferon Epsilon – a new weapon in innate immunity against ovarian cancer - Paul Hertzog
• Using genomic innate immune function (IIF) profiling to predict patient response to immunotherapy - Robyn A Lindley